Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 911-295-9 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
No study on reproduction was available on the reaction mass of octyl and
decyl acrylate.
A read-across with C12C14 Laurylacrylate is proposed for the
fertility/reproduction endpoint.
The results of OECD 422 study on C12C14 Laurylacrylate showed no adverse
effect on reproductive parameters at the highest tested dose (1000
mg/kg/day).
Link to relevant study records
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: US EPA OPPTS 870.3650
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Research Models and Services, Germany GmbH
- Age at study initiation: 10-11 weeks (males/females)
- Fasting period before study: no
- Housing:
During the study period, the rats were housed individually in Makrolon type M III cages supplied by Becker & Co., Castrop-Rauxel, Germany (floor area of about 800 cm²), with the following exceptions:
• During overnight matings, male and female mating partners were housed together in Makrolon type M III cages.
• Pregnant animals and their litters were housed together until PND 4 (end of lactation).
• For motor activity (MA) measurements the animals were housed individually in polycarbonate cages supplied by TECNIPLAST, Hohenpeißenberg, Germany with wire covers from Ehret, Emmendingen, Germany (floor area of about 800 cm2) and small amounts of bedding material (the present supplier is documented in the raw data).
Pregnant females were provided with nesting material (cellulose wadding) toward the end of gestation.
Dust-free wooden bedding was used in this study. Wooden gnawing blocks (Type NGM E-022) supplied by Abed® Lab. and Vet. Service GmbH, Vienna, Austria, were added for environmental enrichment. The cages with the test animals were arranged on the racks in such a way that uniform experimental conditions (ventilation and light) were ensured.
- Diet (ad libitum): ground Kliba maintenance diet mouse-rat “GLP”
- Water (ad libitum): from water bottles
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24
- Humidity (%): 30-70
- Air changes (per hr): 15
- Photoperiod: 12 hours light from 06.00-18.00h, 12 hours dark from 18.00-06.00h
- Acclimation period: 5-6 days before the beginning of the treatment period - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test substance was applied as a solution. To prepare this solution, the appropriate amount of test substance was weighed out depending on the desired concentration. Then, corn oil was filled up to the desired weight, subsequently released with a magnetic stirrer. The test substance preparations were produced at least once a week. - Details on mating procedure:
- - M/F ratio per cage: 1:1
- Length of cohabitation: max 2 weeks
- Proof of pregnancy: A vaginal smear was prepared after each mating and examined for the presence of sperm. The day on which sperm was detected was denoted gestation day (GD) 0 and the following day "GD 1". - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The analyses of the test substance preparations were carried out at the Analytical Chemistry Laboratory of Experimental Toxicology and Ecology of BASF SE, Ludwigshafen, Germany. The study was carried out in compliance with the Principles of Good Laboratory Practice.
The stability of the test substance in corn oil for a period of 7 days at room temperature was confirmed.
Concentration control Analysis of the test substance preparations were performed in samples of all concentrations at the start of the administration period. - Duration of treatment / exposure:
- After the acclimatization period, the test substance was administered orally via gavage to the F0 generation parental animals, daily. The treatment lasted up to one day prior to sacrifice.
- Frequency of treatment:
- daily in the morning
- Details on study schedule:
- no
- Remarks:
- Doses / Concentrations:
0 (vehicle alone), 100, 300 and 1000 mg/kg
Basis:
nominal conc. - No. of animals per sex per dose:
- 10 male and 10 female rats per dose group
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- no
- Positive control:
- No positive control.
- Parental animals: Observations and examinations:
- - Mortality
A check for moribund and dead animals was made twice daily on working days and once daily on Saturdays, Sundays and public holidays. If animals were in a moribund state, they were sacrificed and necropsied.
- Clinical observations
A cageside examination was conducted at least once daily for any signs of morbidity, pertinent behavioral changes and signs of overt toxicity. Abnormalities and changes were documented daily for each affected animal.
The littering and lactation behavior of the dams was generally evaluated in the mornings in combination with the daily clinical inspection of the dams. Only particular findings (e.g. inability to deliver) were documented on an individual dam basis. On weekdays (except public holidays) the parturition behavior of the dams was inspected in the afternoons in addition to the evaluations in the mornings. The day of littering was considered the 24-hour period from about 15.00 h of one day until about 15.00 h of the following day.
- Detailed clinical observations
Detailed clinical observations (DCO) were performed in all animals prior to the administration period and thereafter at weekly intervals. The findings were ranked according to the degree of severity, if applicable. The animals were transferred to a standard arena (50 × 37.5 cm with sides of 25 cm high). The following parameters were examined:
1. abnormal behavior during “handling”
2. fur
3. skin
4. posture
5. salivation
6. respiration
7. activity/arousal level
8. tremors
9. convulsions
10. abnormal movements
11. impairment of gait
12. lacrimation
13. palpebral closure
14. exophthalmus
15. feces (appearance/consistency)
16. urine
17. pupil size
- Food consumption
Generally, food consumption was determined once a week for male and female parental animals, with the following exceptions:
• Food consumption was not determined during the mating period (male and female F0 animals).
• Food consumption of the F0 females with evidence of sperm was determined on GD 0, 7, 14 and 20.
• Food consumption of F0 females, which gave birth to a litter was determined for PND 4.
Food consumption was not determined in females without positive evidence of sperm (during the mating period of dams used in parallel) and females without litter (during the lactation period of dams used in parallel) and in males after the premating period.
- Body weight data
Body weight was determined before the start of the administration period in order to randomize the animals. During the administration period body weight was determined on study day 0 (start of the administration period) and thereafter once a week at the same time of the day (in the morning). The body weight change of the animals was calculated from these results.
The following exceptions are notable for the female animals:
• During the mating period the parental females were weighed on the day of positive evidence of sperm (GD 0) and on GD 7, 14 and 20.
• Females with litter were weighed on the day of parturition (PND 1) and on PND 4.
• Females without a litter and without positive evidence of sperm in the vaginal smear were weighed weekly. These body weight data were solely used for the calculations of the dose volume.
- Functional observational battery
A functional observational battery was performed in the first five male animals per test group, the first 5 female animals with litter of all test groups at the end of the administration period starting at about 10.00 h. The FOB started with passive observations without disturbing the animals, followed by removal from the home cage, open field observations
in a standard arena and sensorimotor tests as well as reflex tests. The findings were ranked according to the degree of severity, if applicable. The observations were performed at random.
- Home cage observations:
The animals were observed in their closed home cages; during this period any disturbing activities (touching the cage or rack, noise) were avoided during these examinations in order not to influence the behavior of the animals. Attention was paid to:
1. Posture
2. Tremors
3. Convulsions
4. Abnormal movements
5. Impairment of gait
Open field observations:
The animals were transferred to a standard arena (50 × 50 cm with sides of 25 cm height) and observed for at least 2 minutes. The following parameters were examined:
1. Behavior when removed from cage
2. Fur
3. Skin
4. Salivation
5. Nose discharge
6. Lacrimation
7. Eyes/ pupilsize
8. Posture
9. Palpebral closure
10. Respiration
11. Tremors
12. Convulsions
13. Abnormal movements/ stereotypes
14. Impairment of gait
15. Activity/ arousal level
16. Feces excreted within 2 minutes (number/ appearance/ consistency)
17. Urine excreted within 2 minutes (amount/ color)
18. Rearing within 2 minutes
- Sensory motor tests/ reflexes:
The animals were then removed from the open field and subjected to following sensory motor or reflex tests:
1. Reaction to an object being moved towards the face (Approach response)
2. Touch sensitivity (Touch response)
3. Vision (Visual placing response)
4. Pupillary reflex
5. Pinna reflex
6. Audition (Auditory startle response)
7. Coordination of movements (Righting response)
8. Behavior during handling
9. Vocalization
10. Pain perception (Tail pinch)
11. Grip strength of forelimbs
12. Grip strength of hindlimbs
13. Landing foot-splay test
14. Other findings
- Motor activity assessment
Motor activity (MA) was also measured from 14:00 h onwards on the same day as the FOB was performed in the first five parental males and females (with litter) per group. Motor activity was measured on the same day as FOB was performed. The examinations were performed using the TSE Labmaster System supplied by TSE Systems GmbH, Bad Homburg, Germany. For this purpose, the animals were placed in new clean polycarbonate cages with a small amount of bedding for the duration of the measurement. Eighteen beams were allocated per cage. The numbers of beam interrupts was counted over 12 intervals of 5 minutes per interval. The sequence in which the animals were placed in the cages was selected at random. On account of the time needed to place the rats in the cages, the starting time was "staggered" for each animal. The measurement period began when the 1st beam was interrupted and finished exactly 1 hour later. No food or water was offered to the animals during these measurements and the measurement room was darkened after the transfer of the last animal.
Clinical pathology
In the morning blood was taken from the retrobulbar venous plexus from fasted animals.
The animals were anaesthetized using isoflurane (Isoba®, Essex GmbH Munich, Germany). The blood sampling procedure and subsequent analysis of blood and serum samples were carried out in a randomized sequence. For urinalysis the individual animals were transferred to metabolism cages (withdrawal of food and water) and urine was collected overnight. Urine samples were evaluated in a randomized sequence. The following examinations were carried out in the first 5 surviving parental males and the first 5 surviving females with litter (in order of delivery) per group:
- Hematology
The following parameters were determined in blood with EDTA-K3 as anticoagulant using a particle counter (Advia 120 model; Bayer, Fernwald, Germany): Furthermore, blood smears were prepared and stained according to WRIGHT without being evaluated, because of non-ambiguous results of the differential blood cell counts measured by the automated instrument. (reference: Hematology: Principles and
Procedures, 6th Edition, Brown AB, Lea & Febiger, Philadelphia, 1993, page 101).
Parameters: Leukocyte count, Erythrocyte count, Hemoglobin, Hematocrit, Mean corpuscular volume, Mean corpuscular
hemoglobin, Mean corpuscular hemoglobin concentration, Platelet count, Differential blood count, Reticulocytes, Prothrombin time
- Clinical chemistry
Parameters: Alanine aminotransferase (ALT) (L-alanine: 2-oxoglutarate aminotransferase; Aspartate aminotransferase (AST) (L-aspartate: 2-oxoglutarate aminotransferase; Alkaline phosphatase (ALP) (orthophosphoric acid monoester phosphohydrolase; ¿-Glutamyltransferase
(GGT) (¿ -glutamyl) peptide: aminoacid-¿- glutamyl-transferase; Sodium (Na+), Potassium, Chloride, Calcium, Inorganic phosphorus, Glucose, Urea, Creatinine, Total bilirubin, Total proteins, Albumin,Total cholesterol, Triglycerides , Biles acids
- Urinalysis (parameters)
pH, Protein, Glucose, Ketones, Urobilinogen, Bilirubin, Blood, Specific gravity, Sediment Color, turbidity, Volume - Oestrous cyclicity (parental animals):
- The pairing partners, the number of mating days until vaginal sperm were detected and gestational status were recorded for F0 females.
- Sperm parameters (parental animals):
- no data
- Litter observations:
- -. Pup number and status at delivery
All pups delivered from the F0 parents were examined as soon as possible on the day of birth to determine the total number of pups and the number of liveborn and stillborn pups in each litter. Pups, which died before the first determination of their status on the day of birth, were defined as stillborn pups.
- Pup viability/mortality
In general, a check was made for any dead or moribund pups twice daily on workdays (once in the morning and once in the afternoon) or as a rule, only in the morning on Saturdays, Sundays or public holidays. The number and percentage of dead pups on the day of birth (PND 0) and of pups dying between PND 1 - 4 (lactation period) were determined. Pups which died accidentally or were sacrificed due to maternal death were not included in these calculations. The number of live pups/litter was calculated on the day after birth, and on lactation day 4. The viability index was calculated.
- Sex ratio
On the day of birth (PND 0) the sex of the pups was determined by observing the distance between the anus and the base of the genital tubercle; normally, the anogenital distance is considerably greater in male than in female pups. The sex of the pups was finally
confirmed at necropsy. The sex ratio was calculated at day 0 and day 4 after birth.
- Pup clinical observations
The live pups were examined daily for clinical symptoms (including gross-morphological findings) during the clinical inspection of the dams.
- Pup body weight data
The pups were weighed on the day after birth (PND 1) and on PND 4. Pups' body weight change was calculated from these results.
The individual weights were always determined at about the same time of the day (in the morning). “Runts” were defined on the basis of the body weights on PND 1. "Runts" are pups that weigh less than 75% of the mean weight of the respective control pups. - Postmortem examinations (parental animals):
- Necropsy
All parental animals were sacrificed by decapitation under isoflurane anesthesia. The exsanguinated animals were necropsied and assessed by gross pathology; special attention was given to the reproductive organs.
Weight parameters
The following weights were determined in all animals sacrificed on schedule:
1. Anesthetized animals
2. Epididymides
3. Testes
The following weights were determined in 5 animals per sex/test group sacrificed on schedule (females with litters only, same animals as used for clinical pathological examinations):
1. Adrenal glands
2. Brain
3. Heart
4. Kidneys
5. Liver
6. Spleen
7. Thymus
Organ/tissue fixation
The following organs or tissues of all parental animals were fixed in 4% buffered formaldehyde solution or modified Davidson’s solution:
1. All gross lesions
2. Adrenal glands
3. Aorta
4. Bone marrow (femur)
5. Brain
6. Cecum
7. Cervix
8. Coagulating gland
9. Colon
10. Duodenum
11. Eyes with optic nerve
12. Esophagus
13. Extraorbital lacrimal glands
14. Epididymides (modified Davidson’s solution)
15. Femur with knee joint
16. Heart
17. Ileum
18. Jejunum (with Peyer’s patches)
19. Kidneys
20. Larynx
21. Liver
22. Lungs
23. Lymph nodes (axillary and mesenteric)
24. Mammary gland (male and female)
25. Nose (nasal cavity)
26. Ovaries (modified Davidson’s solution)
27. Oviducts
28. Pancreas
29. Parathyroid glands
30. Pharynx
31. Pituitary gland
32. Prostate gland
33. Rectum
34. Salivary glands (mandibular and sublingual)
35. Sciatic nerve
36. Seminal vesicles
37. Skeletal muscle
38. Spinal cord (cervical, thoracic and lumbar cord)
39. Spleen
40. Sternum with marrow
41. Stomach (forestomach and glandular stomach)
42. Testes (modified Davidson’s solution)
43. Thymus
44. Thyroid glands
45. Trachea
46. Urinary bladder
47. Uterus
48. Vagina
- Histopathology
Fixation was followed by histotechnical processing, examination by light microscopy and assessment of findings from the following organs of all animals/test group, all animals affected/test group or 5 animals per sex/test group, females with litters only, same animals as used for
clinical pathological examinations.
Special attention was given to stages of spermatogenesis in the male gonads.
A correlation between gross lesions and histopathological findings was attempted.
Organs:
Adrenal glands, All gross lesions, Bone marrow (femur) , Brain, Cecum, Cervix, Coagulating glands, Colon, Duodenum, Epididymides, Heart,
Ileum, Jejunum, Kidneys, Live, Lungs, Lymph nodes (axillary and mesenteric, Ovaries , Oviducts, Prostate gland, Peyer’s patches , Rectum,
Sciatic nerve , Seminal vesicles, Spinal cord (cervical, thoracic, lumbar) , Spleen, Stomach (forestomach and glandular stomach), Testes , Thymus , Thyroid glands , Trachea , Urinary bladder , Uterus , Vagina - Postmortem examinations (offspring):
- - Pup necropsy observations
All pups with scheduled sacrifice on PND 4 were sacrificed under isoflurane anesthesia with CO2. All pups were examined externally and eviscerated; their organs were assessed macroscopically.
All stillborn pups and all pups that died before PND 4 were examined externally, eviscerated and their organs were assessed macroscopically. All pups without notable findings or abnormalities were discarded after their macroscopic evaluation. Animals with notable findings or abnormalities were evaluated on a case-bycase basis, depending on the type of finding noted. - Statistics:
- For parameters with bidirectional changes:
Non-parametric one-way analysis using KRUSKAL-WALLIS test. If the resulting p-value was equal or less than 0.05, a pairwise comparison of each dose group with the control group was performed using WILCOXON-test (twosided) for the hypothesis of equal medians.
For parameters with unidirectional changes:
Pairwise comparison of each dose group with the control group using the WILCOXON-test (one-sided) for the hypothesis of equal medians. - Reproductive indices:
- The following indeces were determined: mating and fertility index for both males and females, gestation index, live birth index
- Offspring viability indices:
- The following indices were determined: sex ratio and viability index
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Detailed clinical observations
One female animal of test group 3 (No.138) showed a swelling of the left mouth region on study days 21 and 28.
Summary clinical observations for males and females
Slight to moderate salivation in 3 male animals of test groups 2 and all male animals of test group 3 was observed after treatment in the pre-mating period.
Slight to moderate salivation in 4 male animals of test groups 2 and all male animals of test group 3 was observed after treatment in the mating period.
Slight to moderate salivation in 5 male animals of test groups 2 and all male animals of test group 3 was observed after treatment in the post-mating period.
Slight to moderate salivation in 1 female animal of test groups 2 and in 7 female animals of test group 3 was observed after treatment in the pre-mating period.
Slight to moderate salivation in 1 female animal of test groups 2 and in 7 female animals of test group 3 was observed after treatment in the mating period.
Animal No. 126 (mated with Animal No. 26) did not show sperm in vaginal smear.
Summary clinical observations for females during gestation
Animal No. 138 of test group 3 showed a swelling of the left mouth region from gestation day 1 to 17. Because of a single incidence this finding was assessed as being incidental.
Animal Nos. 123, 125, 127 and 128 of test group 2 showed slight salivation after treatment. All animals of test group 3 showed slight to moderate salivation after treatment. These findings were substance-related because of the smelling of the test substance, but no adverse effects.
Animal Nos. 123 and 127 of test group 2 and animal No. 131 and 134 of test group 3 did not deliver any pups. These findings were assessed as being spontaneous in nature and without biological relevance.
Animal No. 109 of control group showed apathy and reduced nutritional condition on gestation day 23.
No other clinical signs were observed.
Clinical observations for females during lactation
Animal Nos. 125 and 128 of test group 2 showed slight salivation after treatment on different study days.
Animal Nos. 132, 135, 136, 137, 138, 139 and 140 of test group 3 showed slight to moderate salivation after treatment on different lactation days.
These findings were substance-related because of the smelling of the test substance, but no adverse effects.
Animal No. 109 of the control group showed a complete litter loss after insufficient after-birth and maternal care. Due to the reduced nutritional condition and the apathy, this animal was sacrificed in a moribund state on lactation day 1. - Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- Animal No. 109 was sacrificed in a moribund state on lactation day 1.
No other animal died prematurely in the present study. - Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Body weight of females of test group 2 (300 mg/kg bw/d) was significantly decreased on gestation day 20 (-5.4%).
Body weight change was significantly decreased in females of test group 3 (1000 mg/kg bw/d) when regarding the premating period from day 0 to day 13 (-6.1%).
Due to the lack of dose response relationship these findings were assessed as being incidental. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- The food consumption was significantly increased (+10.7%) on day 7 in males of test group 3 (1000 mg/kg bw/d) during premating period.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- please find details in section 7.5.1 "repeated toxicity"
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- please find details in section 7.5.1 "repeated toxicity"
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- please find details in section 7.5.1 "repeated toxicity"
- Behaviour (functional findings):
- effects observed, non-treatment-related
- Description (incidence and severity):
- please find details in section 7.5.1 "repeated toxicity"
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Animal No. 109 showed multifocal necroses in the kidney correlating to red foci in the macroscopic diagnosis. The uterus was necrotic with inflammation, fetal tissue was no longer recognizable histologically. Both findings are likely to have contributed to the moribund state of this animal.
Male animal Nos.23 and 26 showed macroscopically a focus on the liver which correlated histologically with focal necrosis. This was not considered to be treatment – related as it was focal and not present in test group 3.
All other findings occurred either individually or were biologically equally distributed over control and treatment groups. They were considered to be incidental or spontaneous in origin and without any relation to treatment.
Three mating pairs of test group 2 ([300 mg/kg bw/day] Nos. 23/123, 26/126, 27/127) and two pairs of test group 3 ([1000 mg/kg bw/day] 31/131, 34/134) were recorded as no offspring/ not pregnant. None of the examined animals showed relevant histopathological findings (134 [stomach erosion/ulcus], 23 [liver necrosis], 26 [liver necrosis], 34 [no lesions], 31 [thyroid hypertrophy/hyperplasia, grade 1].
These findings were not considered to be treatment - related and spontaneous in origin. - Histopathological findings: neoplastic:
- not examined
- Other effects:
- not examined
- Reproductive function: oestrous cycle:
- not examined
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- Male mating index
For F0 parental males, which were placed with females to generate F1 pups, mating was confirmed, except for animal No. 26. The male mating index was 90% in test group 2 (300 mg/kg bw/d) and 100% in all other test groups.
This finding reflected the normal range of biological variation inherent in the strain of rats used for this study as all respective values were within the range of the historical control data.
Male fertility index
Fertility was proven for all of the F0 parental males within the scheduled mating interval to produce F1 litter.
Two males of test group 3 (No. 31 mated with 131 and No. 34 mated with No. 134), three males of test group 2 (No. 23 mated with female No. 123, No. 26 mated with female No. 126 and No. 27 mated with No. 127) did not generate F1 pups.
The male fertility index was between the range of 70% and 100%.
This finding reflected the normal range of biological variation inherent in the strain of rats used for this study as all respective values were within the range of the historical control data.
Female mating index
The female mating index calculated after the mating period for F1 litter was between 90% in test group 2 (300 mg/kg bw/d) and 100% for all other test groups. The mean duration until sperm was detected (GD 0) was 2.7, 2.0, 1.6 and 2.0 days in test groups 0 - 3.
Female fertility index
All sperm positive rats delivered pups with the exception of female Nos. 131 and 134 (test group 3; 1000 mg/kg bw/d) and Nos.123, 126 and 127 (test group 2; 300 mg/kg bw/d), which were mated with male Nos. 31, 34 and 23, 26 and 27, did not become pregnant. The female fertility index was 80% in the high dose group, 77.8% in the mid dose group and 100% in the low and control group.
Female animals Nos. 131, 134, and 127 which delivered no pups, showed no implantation sites.
These data reflect the normal range of biological variation inherent in the strain of rats used for this study as all respective values were within the range of the historical control data.
Gestation index
The gestation index was 100% in all test groups. - Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects observed.
- Critical effects observed:
- no
- Reproductive function: oestrous cycle:
- not examined
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- not examined
- Critical effects observed:
- no
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- The surviving F1 pups of any test group did not show adverse clinical signs up to scheduled sacrifice on PND 4.
- Dermal irritation (if dermal study):
- not examined
- Mortality / viability:
- mortality observed, non-treatment-related
- Description (incidence and severity):
- The viability index indicating pup mortality during lactation (PND 0 - 4) was 90% in test group 0 and 100 % in test groups 1 - 3.
The value of test group 0 was in the normal range of biological variation inherent in the strain of rats used for this study. - Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Mean pup body weights/pup body weight changes of all pups in all test groups were comparable to the control group.
In test group 1 (100 mg/kg bw/d) one female runt was seen (Animal No. 118). - Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Two stillborn pups of test group 0 showed post mortem autolysis (Animal no. 109). Two found dead pups of test group 0 (animal No. 109) showed an empty stomach.
These findings were assessed as being spontaneous in nature and without biological relevance, because of the insufficient after-birth and maternal care of the female no. 109. - Histopathological findings:
- not examined
- Other effects:
- not examined
- Behaviour (functional findings):
- not examined
- Developmental immunotoxicity:
- not examined
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects observed.
- Critical effects observed:
- no
- Reproductive effects observed:
- not specified
- Conclusions:
- No maternal toxicity or developmental toxicity, and no effects on reproduction parameters were observed in this study at all tested dose-levels.
- Executive summary:
The objective of the OECD 422 study was to detect possible effects of the test substance on the integrity and performance of male and female reproductive systems including gonadal function, mating behavior, conception, gestation and parturition. Furthermore, it was intended to obtain information about the general toxicological profile including target organs and the no observed adverse effect level (NOAEL) after repeated oral administration. The duration of treatment covered a 2-week pre-mating and mating period in both sexes, approximately 1 week post-mating in males, and the entire gestation period as well as 4 days of lactation and two weeks thereafter in females.
Lauryacrylate 1214 was administered orally via gavage to groups of 10 male and 10 female Wistar rats at dose levels of 0, 100, 300 and 1000 mg/kg bw/d (respectovely test groups 0,1,2 and 3).
Regarding clinical examinations, no signs of general systemic toxicity were observed in male or female parental animals of test groups 1-3 during the entire study period. Regarding fertility and reproductive performance, no signs of toxicity were observed in male or female parental animals of all test groups during the entire study. Regarding developmental toxicity, no biologically relevant signs of toxicity were observed in male or female pups of all test groups. Regarding clinical pathology, no treatment-related, adverse effects were observed up to a dose of the compound of 1000 mg/kg bw/d. Regarding pathology, the liver of male animals of test group 2 and 3 (300 and 1000 mg/kg bw/day, respectively) showed an increase in absolute (group 3 only) and relative weights which was regarded to be adaptive and non-adverse in the absence of histological findings. The NOAEL (no observed adverse effect level) for general, systemic toxicity was 1000 mg/kg bw/d.The NOAEL for reproductive performance and fertility was 1000 mg/kg bw/d for the F0 parental rats.
The NOAEL for developmental toxicity in the F1 progeny was found to be 1000 mg/kg bw/d.
Reference
The mean number of delivered F1 pups was 13.9 (test group 0), 11.9 (test group 1), 10.7 (test group 2) and 10.9 (test group 3).
The decreased values of test group 2 and test group 3 were consequent to the increase of the mean number of delivered pups in the control group, which were higher than the historical control data.
The three stillborn pups in test group 3 and six stillborn pups in test group 0 were incidental and in the normal range of biological variation inherent in the strain of rats used for this study.
Sex ratio
TThe sex distribution and sex ratios of live F1 pups on the day of birth and PND 4 did not show substantial differences between the control and the test substance-treated groups; slight differences were regarded to be spontaneous in nature.
Live birth indices: The live birth index was 100% in all test groups.
Three females (Nos. 133, 135 and 140) in test group 3 (1000 mg/kg bw/d) and two females (Nos. 104 and 109) in test group 0 (0 mg/kg bw/d) with single stillborn and found dead pups were observed.
Postimplantation loss
The postimplantation loss was between 2.96% (test group 0), 3.41% (test group 1), 5.56% (test group 2) and 2.53% (test group 3).
The values were in the range of the historical control data.
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- The study is considered to be reliable with a klimisch score of 1 (reliable without restriction)
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test (OECD 422)
The objective of the OECD 422 study was to detect possible effects of the test substance on the integrity and performance of male and female reproductive systems including gonadal function, mating behavior, conception, gestation and parturition. Furthermore, it was intended to obtain information about the general toxicological profile including target organs and the no observed adverse effect level (NOAEL) after repeated oral administration. The duration of treatment covered a 2-week pre-mating and mating period in both sexes, approximately 1 week post-mating in males, and the entire gestation period as well as 4 days of lactation and two weeks thereafter in females.
Lauryacrylate 1214 was administered orally via gavage to groups of 10 male and 10 female Wistar rats at dose levels of 0, 100, 300 and 1000 mg/kg bw/d (respectovely test groups 0,1,2 and 3).
Regarding clinical examinations, no signs of general systemic toxicity were observed in male or female parental animals of test groups 1-3 during the entire study period. Regarding fertility and reproductive performance, no signs of toxicity were observed in male or female parental animals of all test groups during the entire study. Regarding developmental toxicity, no biologically relevant signs of toxicity were observed in male or female pups of all test groups. Regarding clinical pathology, no treatment-related, adverse effects were observed up to a dose of the compound of 1000 mg/kg bw/d. Regarding pathology, the liver of male animals of test group 2 and 3 (300 and 1000 mg/kg bw/day, respectively) showed an increase in absolute (group 3 only) and relative weights which was regarded to be adaptive and non-adverse in the absence of histological findings.The NOAEL (no observed adverse effect level) for general, systemic toxicity was 1000 mg/kg bw/d.The NOAEL for reproductive performance and fertility was 1000 mg/kg bw/d for the F0 parental rats.
The NOAEL for developmental toxicity in the F1 progeny was found to be 1000 mg/kg bw/d.
Effects on developmental toxicity
Description of key information
No study on developmental toxicity was available the reaction mass of octyl and decyl acrylate.
No developmental test is proposed because not required at the Annexe VIII of REACH Regulation.
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Based on the available data, no classification for the reaction mass of octyl and decyl acrylate is required for reprotoxicity according to the Regulation EC no 1272/2008.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.